IVBXF
Innovent Biologics, Inc. OTC$11.25
Mkt Cap $19.5B
52w Low $5.94
57.8% of range
52w High $15.12
50d MA $10.77
200d MA $11.37
P/E (TTM)
23.9x
EV/EBITDA
50.7x
P/B
0.9x
Debt/Equity
0.1x
ROE
4.8%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
0.23
50d MA
$10.77
200d MA
$11.37
Avg Volume
3.2K
About
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and e…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | 0.02 | -0.00 | -108.4% | 10.62 | +0.0% | +0.0% | -5.8% | +3.5% | +10.2% | +10.4% | — |
| Aug 27, 2025 | AMC | 0.03 | 0.07 | +173.2% | 12.00 | +6.7% | +0.0% | +0.0% | +8.8% | +14.3% | +14.7% | — |
| Mar 26, 2025 | AMC | -0.03 | 0.03 | +179.4% | 5.20 | +8.7% | +13.5% | +13.5% | +13.5% | +18.3% | +18.3% | — |
| Aug 28, 2024 | AMC | -0.03 | -0.03 | +3.2% | 5.50 | +0.0% | +0.0% | -4.5% | -3.8% | -3.8% | +1.5% | — |
| Mar 20, 2024 | AMC | -0.07 | -0.08 | -12.5% | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | -0.10 | -0.01 | +87.3% | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | -0.17 | -0.12 | +30.7% | — | — | — | — | — | — | — | — |
| Jun 30, 2022 | AMC | -0.15 | -0.10 | +36.4% | 4.05 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Dec 31, 2021 | AMC | -0.14 | -0.19 | -29.5% | 6.15 | -5.2% | -6.2% | -17.7% | -17.2% | -16.4% | -16.4% | — |
| Jun 30, 2021 | AMC | -0.04 | -0.11 | -188.2% | 11.90 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
Data updated apr 28, 2026 12:43pm
· Source: massive.com